Contact Details
- Phone
- +64 3 479 8524
- michelle.glass@otago.ac.nz
- Position
- Professor
- Department
- Department of Pharmacology and Toxicology
- Qualifications
- PhD BSc
- Research summary
- Cannabinoids, neurodegenerative diseases, Huntington’s disease, G-protein coupled receptors
Research
Michelle Glass is a molecular pharmacologist who joined the Department of Pharmacology and Toxicology at the University of Otago as Head of Department in 2018, moving here from the University of Auckland where she worked for 18 years.
She returned to the department where her working career began 23 years ago. Professor Glass’ first role after graduating with a PhD from the Department of Pharmacology at the University of Auckland in 1995 was as an Assistant Lecturer in the Department of Pharmacology at the University of Otago.
Her initial stint at Otago was brief as she took up a fellowship in the United States the following year. She worked as a postdoctoral Fellow in the Laboratory of Cellular and Molecular Regulation at the National Institute of Mental Health in Bethesda, Maryland for 18 months before moving on to work as a Visiting Fellow in the Laboratory of Cell Biology at the National Institute of Deafness and Other Communications Disorders in Rockville, Maryland. She returned to New Zealand in 2000 and took up a role as a Lecturer within the Department of Pharmacology at the University of Auckland.
Professor Glass’ research focuses on the expression, function and molecular pharmacology of the cannabinoid receptors and their potential role in treatment of neurodegenerative diseases. Her recent research interests have extended to identifying the mechanism by which synthetic cannabinoids are resulting in high levels of toxicity in the community and advising on the development of clinical trials for medicinal cannabis products.
Currently, Professor Glass is a member of the Medical Cannabis Research Collaborative (NZ), which aims to ensure robust clinical research of medical cannabis products in New Zealand is undertaken. It will also set informal standards for the development and testing of medical cannabis products, as well as increasing understanding and the base of evidence for or against the use of medical cannabis products in specific clinical conditions. Her contributions to the field have been acknowledged by an early career award from the International Cannabinoid Research Society in 2009 and by election to President of this society.
She acknowledges it is an interesting time with change potentially in the wind with so many countries legalising cannabis.
“I think it’s important that the science keeps up with the public debate.”
Read more in Otago Bulletin:
Synthetic cannabis under spotlight for new Pharmacology head
Publications
Patel, M., Zheng, X., Akinfiresoye, L. R., Prioleau, C., Walker, T. D., Glass, M., & Marusich, J. A. (2024). Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists. European Journal of Pharmacology, 971, 176549. doi: 10.1016/j.ejphar.2024.176549
Ryalls, B., Patel, M., Sparkes, E., Banister, S. D., Finlay, D. B., & Glass, M. (2024). Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor. Biochemical Pharmacology, 222, 116052. doi: 10.1016/j.bcp.2024.116052
Green, H. M., Fellner, D. M. J., Finlay, D. B., Furkert, D. P., & Glass, M. (2024). Determination of the cannabinoid CB1 receptor's positive allosteric modulator binding site through mutagenesis studies. Pharmaceuticals, 17, 154. doi: 10.3390/ph17020154
Green, H. M., Yang, L., Zhu, X., Finlay, D. B., Duffull, S. B., & Glass, M. (2024). Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model. Naunyn-Schmiedeberg's Archives of Pharmacology. Advance online publication. doi: 10.1007/s00210-023-02923-6
Yang, L., Finlay, D. B., Green, H. M., Zhu, X., Glass, M., & Duffull, S. (2023). A quantitative pharmacology model for cannabinoid CB1 receptor mediated by Gi/Gs protein competition. British Journal of Pharmacology. Advance online publication. doi: 10.1111/bph.16293
Lu, D., & Glass, M. (2023). Org27569, the allosteric modulators and the cannabinoid receptor 1 (CB1). In V. B. Patel, V. R. Preedy & C. R. Martin (Eds.), Neurobiology and physiology of the endocannabinoid system. (pp. 365-377). London, UK: Academic Press. doi: 10.1016/B978-0-323-90877-1.00015-2
Chapter in Book - Research
Ashton, J. C., Dowie, M. J., & Glass, M. (2017). The endocannabinoid system and human brain functions: Insight from memory, motor, and mood pathologies. In E. Murillo-Rodríguez (Ed.), The endocannabinoid system. (pp. 115-186). London, UK: Academic Press. doi: 10.1016/B978-0-12-809666-6.00005-8
Chapter in Book - Research
Cawston, E. E., Hunter, M. R., & Glass, M. (2017). Allosteric modulation of the cannabinoid CB1 receptor. In V. R. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment. (pp. 573-583). London, UK: Academic Press. doi: 10.1016/B978-0-12-800756-3.00070-3
Chapter in Book - Research
Hunter, M. R., Finlay, D. B., & Glass, M. (2017). Signal transduction and regulation of the cannabinoid CB1 receptor. In V. R. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment. (pp. 563-572). London, UK: Academic Press. doi: 10.1016/B978-0-12-800756-3.00069-7
Chapter in Book - Research
Hunter, M. R., Finlay, D. B., Macdonald, C. E., Cawston, E. E., Grimsey, N. L., & Glass, M. (2017). Real-time measurement of cannabinoid receptor-mediated cAMP signaling. In P. H. Reggio (Ed.), Methods in enzymology: Cannabinoids and their receptors (Vol. 593). (pp. 43-59). Cambridge, MA: Academic Press. doi: 10.1016/bs.mie.2017.05.001
Chapter in Book - Research
Kho, D. T., Glass, M., & Graham, E. S. (2017). Is the cannabinoid CB2 receptor a major regulator of the neuroinflammatory axis of the neurovascular unit in humans? In D. Kendall & S. P. H. Alexander (Eds.), Advances in Pharmacology [Vol. 80: Cannabinoid pharmacology]. (pp. 207-221). Cambridge, MA: Academic Press. doi: 10.1016/bs.apha.2017.03.005
Chapter in Book - Research
Priestley, R., Glass, M., & Kendall, D. (2017). Functional selectivity at cannabinoid receptors. In D. Kendall & S. P. H. Alexander (Eds.), Advances in Pharmacology [Vol. 80: Cannabinoid pharmacology]. (pp. 207-221). Cambridge, MA: Academic Press. doi: 10.1016/bs.apha.2017.03.005
Chapter in Book - Research
Goodfellow, C. E., & Glass, M. (2009). Anandamide receptor signal transduction. In G. Litwack (Ed.), Vitamins and hormones. (pp. 79-110). London, UK: Academic Press. doi: 10.1016/S0083-6729(09)81004-2
Chapter in Book - Research
Ashton, J. C., & Glass, M. (2008). Multiple roles for cannabinoids in neuroprotection during oxidative stress injury. In O. M. Roux (Ed.), Brain hypoxia-ischemia research progress. (pp. 229-244). New York: Nova.
Chapter in Book - Research
Green, H. M., Fellner, D. M. J., Finlay, D. B., Furkert, D. P., & Glass, M. (2024). Determination of the cannabinoid CB1 receptor's positive allosteric modulator binding site through mutagenesis studies. Pharmaceuticals, 17, 154. doi: 10.3390/ph17020154
Journal - Research Article
Green, H. M., Yang, L., Zhu, X., Finlay, D. B., Duffull, S. B., & Glass, M. (2024). Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model. Naunyn-Schmiedeberg's Archives of Pharmacology. Advance online publication. doi: 10.1007/s00210-023-02923-6
Journal - Research Article
Patel, M., Zheng, X., Akinfiresoye, L. R., Prioleau, C., Walker, T. D., Glass, M., & Marusich, J. A. (2024). Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists. European Journal of Pharmacology, 971, 176549. doi: 10.1016/j.ejphar.2024.176549
Journal - Research Article
Ryalls, B., Patel, M., Sparkes, E., Banister, S. D., Finlay, D. B., & Glass, M. (2024). Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor. Biochemical Pharmacology, 222, 116052. doi: 10.1016/j.bcp.2024.116052
Journal - Research Article
Finlay, D. B., Mackie, W., Webb, H. D. J., Thomsen, L. R., Nimick, M., Rosengren, R. J., … Glass, M., & Wiley, J. L. (2023). The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism. Pharmacology Biochemistry & Behavior. Advance online publication. doi: 10.1016/j.pbb.2023.173530
Journal - Research Article
Haney, M., Vallée, M., Fabre, S., Collins Reed, S., Zanese, M., Campistron, G., … Finlay, D. B., … Glass, M., … Piazza, P. V. (2023). Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: Phase 1 and phase 2a randomized trials. Nature Medicine. Advance online publication. doi: 10.1038/s41591-023-02381-w
Journal - Research Article
Manning, J. J., Rawcliffe, G., Finlay, D. B., & Glass, M. (2023). Cannabinoid type-1 receptor arrestin subtype-selectivity and phosphorylation dependence. British Journal of Pharmacology, 180, 369-382. doi: 10.1111/bph.15973
Journal - Research Article
Patel, M., Grimsey, N. L., Banister, S. D., Finlay, D. B., & Glass, M. (2023). Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor. Pharmacology Research & Perspectives, 11, e01157. doi: 10.1002/prp2.1157
Journal - Research Article
Webb, H. D. J., Finlay, D. B., Chen, S., Vernall, A. J., Sparkes, E., Banister, S. D., Rosengren, R. J., & Glass, M. (2023). Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite. Forensic Toxicology, 41, 114-125. doi: 10.1007/s11419-022-00649-3
Journal - Research Article
Yang, L., Finlay, D. B., Green, H. M., Zhu, X., Glass, M., & Duffull, S. (2023). A quantitative pharmacology model for cannabinoid CB1 receptor mediated by Gi/Gs protein competition. British Journal of Pharmacology. Advance online publication. doi: 10.1111/bph.16293
Journal - Research Article
Yang, L., Zhu, X., Finlay, D. B., Green, H., Glass, M., & Duffull, S. B. (2023). A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid receptor (CB1). British Journal of Pharmacology, 180, 2661-2676. doi: 10.1111/bph.16158
Journal - Research Article
Finlay, D. B., Nguyen, T., Gamage, T. F., Chen, S., Barrus, D. G., Patel, P. R., … Glass, M. (2022). Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Research & Perspectives, 10, e00901. doi: 10.1002/prp2.901
Journal - Research Article
Green, H. M., Finlay, D. B., Ross, R. A., Greig, I. R., Duffull, S. B., & Glass, M. (2022). In vitro characterization of 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1 H-indole (ZCZ011) at the type 1 cannabinoid receptor: Allosteric agonist or allosteric modulator? ACS Pharmacology & Translational Science, 5, 1279-1291. doi: 10.1021/acsptsci.2c00160
Journal - Research Article
Kevin, R. C., Mirlohi, S., Manning, J. J., Boyd, R., Cairns, E. A., Ametovski, A., … Glass, M., … Banister, S. D. (2022). Putative synthetic cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and their analogues are T-type calcium channel (CaV3) inhibitors. ACS Chemical Neuroscience, 13, 1395-1409. doi: 10.1021/acschemneuro.1c00822
Journal - Research Article
Markham, J., Sparkes, E., Boyd, R., Chen, S., Manning, J. J., Finlay, D., … Glass, M., … Banister, S. D. (2022). Defining steric requirements at CB1 and CB2 cannabinoid receptors using synthetic cannabinoid receptor agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and their analogues. ACS Chemical Neuroscience, 13, 1281-1295. doi: 10.1021/acschemneuro.2c00034
Journal - Research Article
Nguyen, T., Gamage, T. F., Finlay, D. B., Decker, A. M., Langston, T. L., Barrus, D., Glass, M., … Zhang, Y. (2022). Development of 3-(4-chlorophenyl)-1-(phenethyl)urea analogues as allosteric modulators of the cannabinoid type-1 receptor: RTICBM-189 is brain penetrant and attenuates reinstatement of cocaine-seeking behavior. Journal of Medicinal Chemistry, 65, 257-270. doi: 10.1021/acs.jmedchem.1c01432
Journal - Research Article
Shirazi, R. S., Vyssotski, M., Lagutin, K., Thompson, D., MacDonald, C., Luscombe, V., Glass, M., … Gowing, E. K., … Clarkson, A. N. (2022). Neuroprotective activity of new Δ3-N-acylethanolamines in a focal ischemia stroke model. Lipids, 57, 17-31. doi: 10.1002/lipd.12326
Journal - Research Article
Sparkes, E., Boyd, R., Chen, S., Markham, J. W., Luo, J. L., Foyzun, T., … Glass, M., … Banister, S. D. (2022). Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs. Frontiers in Psychiatry, 13, 1010501. doi: 10.3389/fpsyt.2022.1010501
Journal - Research Article
Sparkes, E., Cairns, E. A., Kevin, R. C., Lai, F., Grafinger, K. E., Chen, S., … Glass, M., … Banister, S. D. (2022). Structure-activity relationships of valine-, tert-leucine-, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Medicinal Chemistry, 13, 156-174. doi: 10.1039/D1MD00242B
Journal - Research Article
Ametovski, A., Cairns, E. A., Grafinger, K. E., Cannaert, A., Deventer, M. H., Chen, S., … Glass, M., … Banister, S. D. (2021). NNL-3: A synthetic intermediate or a new class of hydroxybenzotriazole esters with cannabinoid receptor activity? ACS Chemical Neuroscience, 12, 4020-4036. doi: 10.1021/acschemneuro.1c00348
Journal - Research Article
Manning, J. J., Green, H. M., Glass, M., & Finlay, D. B. (2021). Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias. Neuropharmacology, 193, 108611. doi: 10.1016/j.neuropharm.2021.108611
Journal - Research Article
Mielnik, C. A., Sugamori, K. S., Finlay, D. B., Thorpe, H. H. A., Schapira, M., Sivananthan, N., … Glass, M., … Ross, R. A. (2021). A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models. Neuropsychopharmacology, 46, 413-422. doi: 10.1038/s41386-020-00876-5
Journal - Research Article
Nguyen, T., Gamage, T. F., Decker, A. M., Finlay, D. B., Langston, T. L., Barrus, D., Glass, M., … Zhang, Y. (2021). Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. Bioorganic & Medicinal Chemistry, 41, 116215. doi: 10.1016/j.bmc.2021.116215
Journal - Research Article
Patel, M., Finlay, D. B., & Glass, M. (2021). Biased agonism at the cannabinoid receptors: Evidence from synthetic cannabinoid receptor agonists. Cellular Signaling, 78, 109865. doi: 10.1016/j.cellsig.2020.109865
Journal - Research Article
Patel, M., Matti, C., Grimsey, N. L., Legler, D. F., Javitch, J. A., Finlay, D. B., & Glass, M. (2021). Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors: β‐arrestins and GPCR kinases. British Journal of Pharmacology, 179, 2223-2239. doi: 10.1111/bph.15748
Journal - Research Article
Robson, H., Braund, R., Glass, M., Ashton, J., & Tatley, M. (2021). Synthetic cannabis: Adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical Toxicology, 59(6), 472-479. doi: 10.1080/15563650.2020.1828592
Journal - Research Article
Singh, S., Liddle, I., Macdonald, C., Tyndall, J. D. A., Glass, M., & Vernall, A. (2021). Development of chromenopyrazole-based selective cannabinoid 2 receptor agonists. Australian Journal of Chemistry, 74, 433-442. doi: 10.1071/CH20263
Journal - Research Article
Yang, L., Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2021). Exploring group size for statistical analysis of real-time signalling experiments. British Journal of Pharmacology, 178, 3997-4004. doi: 10.1111/bph.15572
Journal - Research Article
Ametovski, A., Macdonald, C., Manning, J. J., Syed Haneef, S. A., Santiago, M., Martin, L., … Glass, M., & Banister, S. D. (2020). Exploring stereochemical and conformational requirements at cannabinoid receptors for synthetic cannabinoids relating to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. ACS Chemical Neuroscience, 11, 3672-3682. doi: 10.1021/acschemneuro.0c00591
Journal - Research Article
Finlay, D. B., Sircombe, K. J., Nimick, M., Jones, C., & Glass, M. (2020). Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Frontiers in Pharmacology, 11, 359. doi: 10.3389/fphar.2020.00359
Journal - Research Article
Gamage, T. F., Barrus, D. A., Kevin, R. C., Finlay, D. B., Lefever, T. W., Patel, P. R., … Glass, M., … Thomas, B. F. (2020). In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Biochemistry & Behavior, 193, 172918. doi: 10.1016/j.pbb.2020.172918
Journal - Research Article
Narayan, P., Reid, S., Scotter, E. L., McGregor, A. L., Mehrabi, N. F., Singh-Bains, M. K., Glass, M., … Dragunow, M. (2020). Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brains. Neurobiology of Disease, 146, 105092. doi: 10.1016/j.nbd.2020.105092
Journal - Research Article
Ong, R. S., Kappatos, D. C., Russell, S. G. G., Poulsen, H. A., Banister, S. D., Gerona, R. R., Glass, M., … McCarthy, M.-J. (2020). Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry: A New Zealand perspective of use in 2018. Drug Testing & Analysis, 12, 195-214. doi: 10.1002/dta.2697
Journal - Research Article
Patel, M., Manning, J. J., Finlay, D. B., Javitch, J. A., Banister, S. D., Grimsey, N. L., & Glass, M. (2020). Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 175, 113871. doi: 10.1016/j.bcp.2020.113871
Journal - Research Article
Van den Berg, M., John, M., Black, M., Semprini, A., Oldfield, K., Glass, M., & Braithwaite, I. (2020). Cannabis-based medicinal products in arthritis, a painful conundrum. New Zealand Medical Journal, 133(1515), 35-45. Retrieved from https://www.nzma.org.nz/journal
Journal - Research Article
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2020). Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling. British Journal of Pharmacology, 177, 3449-3463. doi: 10.1111/bph.15066
Journal - Research Article
Banister, S. D., Adams, A., Kevin, R. C., Macdonald, C., Glass, M., Boyd, R., … Gerona, R. R. (2019). Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA. Drug Testing & Analysis, 11(2), 279-291. doi: 10.1002/dta.2491
Journal - Research Article
Finlay, D. B., Manning, J. J., Ibsen, M. S., Macdonald, C. E., Patel, M., Javitch, J. A., … Glass, M. (2019). Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chemical Neuroscience, 10, 4350-4360. doi: 10.1021/acschemneuro.9b00429
Journal - Research Article
Ibsen, M. S., Finlay, D. B., Patel, M., Javtich, J. A., Glass, M., & Grimsey, N. L. (2019). Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: Species, subtype, and agonist-dependence. Frontiers in Pharmacology, 10, 350. doi: 10.3389/fphar.2019.00350
Journal - Research Article
Kevin, R. C., Anderson, L., McGregor, I. S., Boyd, R., Manning, J. J., Glass, M., … Banister, S. D. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10, 595. doi: 10.3389/fphar.2019.00595
Journal - Research Article
Saroz, Y., Kho, D. T., Glass, M., Graham, E. S., & Grimsey, N. L. (2019). Cannabinoid receptor 2 (CB2) signals via G-alpha-s and induces IL-6 and IL-10 cytokine secretion in human primary leukocytes. ACS Pharmacology & Translational Science, 2(6), 414-428. doi: 10.1021/acsptsci.9b00049
Journal - Research Article
Singh, S., Oyagawa, C. R. M., Macdonald, C., Grimsey, N. L., Glass, M., & Vernall, A. J. (2019). Chromenopyrazole-based high affinity, selective fluorescent ligands for cannabinoid type 2 receptor. ACS Medicinal Chemistry Letters, 10, 209-214. doi: 10.1021/acsmedchemlett.8b00597
Journal - Research Article
Wiley, J. L., Lefever, T. W., Glass, M., & Thomas, B. F. (2019). Do you feel it now? Route of administration and Δ9-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice. NeuroToxicology, 73, 161-167. doi: 10.1016/j.neuro.2019.04.002
Journal - Research Article
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). An intact model for quantifying functional selectivity. Scientific Reports, 9, 2557. doi: 10.1038/s41598-019-39000-z
Journal - Research Article
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors. British Journal of Pharmacology, 176, 2593-2607. doi: 10.1111/bph.14684
Journal - Research Article
Cooper, A. G., MacDonald, C., Glass, M., Hook, S., Tyndall, J. D. A., & Vernall, A. J. (2018). Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. European Journal of Medicinal Chemistry, 145, 770-789. doi: 10.1016/j.ejmech.2017.11.076
Journal - Research Article
Cooper, A. G., Oyagawa, C. R. M., Manning, J. J., Singh, S., Hook, S., Grimsey, N. L., Glass, M., Tyndall, J. D. A., & Vernall, A. J. (2018). Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. MedChemComm, 9(12), 2055-2067. doi: 10.1039/c8md00448j
Journal - Research Article
Hosie, S., Malone, D. T., Liu, S., Glass, M., Adlard, P. A., Hannan, A. J., & Hill-Yardin, E. L. (2018). Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3 R451C mouse model of autism. Frontiers in Cellular Neuroscience, 12, 234. doi: 10.3389/fncel.2018.00234
Journal - Research Article
Oyagawa, C. R. M., de la Harpe, S. M., Saroz, Y., Glass, M., Vernall, A. J., & Grimsey, N. L. (2018). Cannabinoid Receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines. Frontiers in Pharmacology, 9, 1202. doi: 10.3389/fphar.2018.01202
Journal - Research Article
Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2018). An evaluation of the operational model when applied to quantify functional selectivity. British Journal of Pharmacology, 175, 1654-1668. doi: 10.1111/bph.14171
Journal - Research Article
Finlay, D. B., Cawston, E. E., Grimsey, N. L., Hunter, M. R., Korde, A., Vemuri, V. K., … Glass, M. (2017). Gαs signalling of the CB1 receptor and the influence of receptor number. British Journal of Pharmacology, 174(15), 2545-2562. doi: 10.1111/bph.13866
Journal - Research Article
Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., … Finlay, D., … Glass, M., & van der Stelt, M. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications, 8, 13958. doi: 10.1038/ncomms13958
Journal - Research Article
Banister, S. D., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., … Glass, M., … Kassiou, M. (2016). Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. doi: 10.1021/acschemneuro.6b00137
Journal - Research Article
Finlay, D. B., Joseph, W. R., Grimsey, N. L., & Glass, M. (2016). GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-arachidonoyl glycine. PeerJ, 2016(4), e1835. doi: 10.7717/peerj.1835
Journal - Research Article
Hunter, M. R., Grimsey, N. L., & Glass, M. (2016). Sulfation of the FLAG epitope is affected by co-expression of G protein-coupled receptors in a mammalian cell model. Scientific Reports, 6, 27316. doi: 10.1038/srep27316
Journal - Research Article
Longworth, M., Banister, S. D., Mack, J. B. C., Glass, M., Connor, M., & Kassiou, M. (2016). The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicology, 34(2), 286-303. doi: 10.1007/s11419-016-0316-y
Journal - Research Article
Redmond, W. J., Cawston, E. E., Grimsey, N. L., Stuart, J., Edington, A. R., Glass, M., & Connor, M. (2016). Identification of N‐arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. British Journal of Pharmacology, 173(1), 115-127. doi: 10.1111/bph.13341
Journal - Research Article
Banister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E., Longworth, M., … Glass, M., … Kassiou, M. (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. doi: 10.1021/acschemneuro.5b00112
Journal - Research Article
Banister, S. D., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., … Glass, M., … Kassiou, M. (2015). Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 33(2), 355-366. doi: 10.1007/s11419-015-0282-9
Journal - Research Article
Banister, S. D., Stuart, J., Kevin, R. C., Edington, A., Longworth, M., Wilkinson, S. M., … Glass, M., … Kassiou, M. (2015). Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. doi: 10.1021/acschemneuro.5b00107
Journal - Research Article
Cawston, E. E., Connor, M., Di Marzo, V., Silvestri, R., & Glass, M. (2015). Distinct temporal fingerprint for cyclic adenosine monophosphate (cAMP) signaling of indole-2-carboxamides as allosteric modulators of the cannabinoid receptors. Journal of Medicinal Chemistry, 58(15), 5979-5988. doi: 10.1021/acs.jmedchem.5b00579
Journal - Research Article
Khajehali, E., Malone, D. T., Glass, M., Sexton, P. M., & Christopoulos, A. (2015). Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Molecular Pharmacology, 88(2), 368-379. doi: 10.1124/mol.115.099192
Journal - Research Article
Dowie, M. J., Grimsey, N. L., Hoffman, T., Faull, R. L. M., & Glass, M. (2014). Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. Journal of Chemical Neuroanatomy, 59-60, 62-71. doi: 10.1016/j.jchemneu.2014.06.004
Journal - Research Article
MacDonald, C., Finlay, D. B., Jabed, A., Glass, M., & Graham, E. S. (2014). Development of positive control tissue for in situ hybridisation using Alvetex scaffolds. Journal of Neuroscience Methods, 238, 70-77. doi: 10.1016/j.jneumeth.2014.09.006
Journal - Research Article
Yee, A. G., Lee, S.-M., Hunter, M. R., Glass, M., Freestone, P. S., & Lipski, J. (2014). Effects of the Parkinsonian toxin MPP+ on electrophysiological properties of nigral dopaminergic neurons. NeuroToxicology, 45, 1-11. doi: 10.1016/j.neuro.2014.08.009
Journal - Research Article
Young, D., Fong, D. M., Lawlor, P. A., Wu, A., Mouravlev, A., McRae, M., Glass, M., … During, M. J. (2014). Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy. Gene Therapy, 21(12), 1029-1040. doi: 10.1038/gt.2014.82
Journal - Research Article
Banister, S. D., Wilkinson, S. M., Longworth, M., Stuart, J., Apetz, N., English, K., … Glass, M., … Kassiou, M. (2013). The synthesis and pharmacological evaluation of adamantane-derived indoles: Cannabimimetic drugs of abuse. ACS Chemical Neuroscience, 4(7), 1081-1092. doi: 10.1021/cn400035r
Journal - Research Article
Cawston, E. E., Redmond, W. J., Breen, C. M., Grimsey, N. L., Connor, M., & Glass, M. (2013). Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. British Journal of Pharmacology, 170(4), 893-907. doi: 10.1111/bph.12329
Journal - Research Article
Graham, E. S., Woo, K. K., Aalderink, M., Fry, S., Greenwood, J. M., Glass, M., & Dragunow, M. (2013). M1 muscarinic receptor activation mediates cell death in M1-HEK293 cells. PLoS ONE, 8(9), e72011. doi: 10.1371/journal.pone.0072011
Journal - Research Article
Grimsey, N. L., Moodley, K. S., Glass, M., & Graham, E. S. (2012). Sensitive and accurate quantification of human leukocyte migration using high-content discovery-1 imaging system and ATPlite assay. Journal of Biomolecular Screening, 17(3), 386-393. doi: 10.1177/1087057111428985
Journal - Research Article
Horváth, B., Magid, L., Mukhopadhyay, P., Bátkai, S., Rajesh, M., Park, O., … Glass, M., … Pacher, P. (2012). A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. British Journal of Pharmacology, 165(8), 2462-2478. doi: 10.1111/j.1476-5381.2011.01381.x
Journal - Research Article
Goodfellow, C. E., Graham, S. E., Dragunow, M., & Glass, M. (2011). Characterization of NTera2/D1 cells as a model system for the investigation of cannabinoid function in human neurons and astrocytes. Journal of Neuroscience Research, 89(10), 1685-1697. doi: 10.1002/jnr.22692
Journal - Research Article
Grimsey, N. L., Goodfellow, C. E., Dragunow, M., & Glass, M. (2011). Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochimica et Biophysica Acta: Molecular Cell Reserch, 1813(8), 1554-1560. doi: 10.1016/j.bbamcr.2011.05.010
Journal - Research Article
Moodley, K., Angel, C. E., & Glass, M. (2011). Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. Journal of Neuroscience Methods, 200(2), 173-180. doi: 10.1016/j.jneumeth.2011.07.005
Journal - Research Article
Dowie, M. J., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2010). Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience, 170(1), 324-336. doi: 10.1016/j.neuroscience.2010.06.056
Journal - Research Article
Dowie, M. J., Scotter, E. L., Molinari, E., & Glass, M. (2010). The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacology & Therapeutics, 128(2), 305-323. doi: 10.1016/j.pharmthera.2010.07.008
Journal - Research Article
Graham, E. S., Angel, C. E., Schwarcz, L. E., Dunbar, P. R., & Glass, M. (2010). Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. International Journal of Immunopathology & Pharmacology, 23(1), 25-34. doi: 10.1177/039463201002300103
Journal - Research Article
Grimsey, N. L., Graham, E. S., Dragunow, M., & Glass, M. (2010). Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: Implications for therapeutics. Biochemical Pharmacology, 80(7), 1050-1062. doi: 10.1016/j.bcp.2010.06.007
Journal - Research Article
Scotter, E. L., Abood, M. E., & Glass, M. (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. British Journal of Pharmacology, 160(3), 480-498. doi: 10.1111/j.1476-5381.2010.00735.x
Journal - Research Article
Scotter, E. L., Goodfellow, C. E., Graham, E. S., Dragunow, M., & Glass, M. (2010). Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. British Journal of Pharmacology, 160(3), 747-761. doi: 10.1111/j.1476-5381.2010.00773.x
Journal - Research Article
Allen, K. L., Waldvogel, H. J., Glass, M., & Faull, R. L. M. (2009). Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington's disease. Journal of Chemical Neuroanatomy, 37(4), 266-281. doi: 10.1016/j.jchemneu.2009.02.001
Journal - Research Article
Dowie, M. J., Bradshaw, H. B., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2009). Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience, 163(1), 456-465. doi: 10.1016/j.neuroscience.2009.06.014
Journal - Research Article
Graham, E. S., Ashton, J. C., & Glass, M. (2009). Cannabinoid receptors: A brief history and 'What's hot'. Frontiers in Bioscience, 14, 944-957. doi: 10.2741/3288
Journal - Research Article
Chamley, L. W., Bhalla, A., Stone, P. R., Liddell, H., O’Carroll, S., Kearn, C., & Glass, M. (2008). Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage. Placenta, 29(11), 970-975. doi: 10.1016/j.placenta.2008.08.003
Journal - Research Article
Grimsey, N. L., Goodfellow, C. E., Scotter, E. L., Dowie, M. J., Glass, M., & Graham, E. S. (2008). Specific detection of CB1 receptors: Cannabinoid CB1 receptor antibodies are not all created equal! Journal of Neuroscience Methods, 171(1), 78-86. doi: 10.1016/j.jneumeth.2008.02.014
Journal - Research Article
Mitchell, M. D., Sato, T. A., Wang, A., Keelan, J. A., Ponnampalam, A. P., & Glass, M. (2008). Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism. American Journal of Physiology: Endocrinology & Metabolism, 294(2), E352-E356. doi: 10.1152/ajpendo.00495.2007
Journal - Research Article
Scotter, E. L., Narayan, P. J., Glass, M., & Dragunow, M. (2008). High throughput quantification of mutant huntingtin aggregates. Journal of Neuroscience Methods, 171(1), 174-179. doi: 10.1016/j.jneumeth.2008.02.007
Journal - Research Article
Ashton, J. C., & Glass, M. (2007). The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Current Neuropharmacology, 5(2), 73-80.
Journal - Research Article
Ashton, J. C., Rahman, R. M. A., Nair, S. M., Sutherland, B. A., Glass, M., & Appleton, I. (2007). Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neuroscience Letters, 412, 114-117.
Journal - Research Article
McPartland, J. M., Glass, M., & Pertwee, R. B. (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: Interspecies differences. British Journal of Pharmacology, 152(5), 583-593. doi: 10.1038/sj.bjp.0707399
Journal - Research Article
McPartland, J. M., Glass, M., Matias, I., Norris, R. W., & Kilpatrick, C. W. (2007). A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio). Molecular Genetics & Genomics, 277(5), 555-570. doi: 10.1007/s00438-007-0207-3
Journal - Research Article